vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.
UL Solutions Inc. is the larger business by last-quarter revenue ($340.0M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -12.4%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -31.8%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.
PCRX vs ULS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $340.0M |
| Net Profit | $2.9M | — |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 24.4% |
| Net Margin | 1.6% | — |
| Revenue YoY | 5.0% | -12.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $340.0M | ||
| Q4 25 | $196.9M | $789.0M | ||
| Q3 25 | $179.5M | $783.0M | ||
| Q2 25 | $181.1M | $776.0M | ||
| Q1 25 | $168.9M | $705.0M | ||
| Q4 24 | $187.3M | $739.0M | ||
| Q3 24 | $168.6M | $731.0M | ||
| Q2 24 | $178.0M | $730.0M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $67.0M | ||
| Q3 25 | $5.4M | $100.0M | ||
| Q2 25 | $-4.8M | $91.0M | ||
| Q1 25 | $4.8M | $67.0M | ||
| Q4 24 | — | $81.0M | ||
| Q3 24 | $-143.5M | $88.0M | ||
| Q2 24 | $18.9M | $101.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 49.7% | ||
| Q3 25 | 80.9% | 50.3% | ||
| Q2 25 | 77.4% | 49.4% | ||
| Q1 25 | 79.7% | 48.4% | ||
| Q4 24 | 78.7% | 47.4% | ||
| Q3 24 | 76.9% | 49.0% | ||
| Q2 24 | 75.1% | 50.1% |
| Q1 26 | 3.9% | 24.4% | ||
| Q4 25 | 1.2% | 15.0% | ||
| Q3 25 | 3.5% | 19.9% | ||
| Q2 25 | 4.7% | 17.9% | ||
| Q1 25 | 1.2% | 15.5% | ||
| Q4 24 | 13.2% | 15.6% | ||
| Q3 24 | -82.8% | 17.8% | ||
| Q2 24 | 15.9% | 17.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 8.5% | ||
| Q3 25 | 3.0% | 12.8% | ||
| Q2 25 | -2.7% | 11.7% | ||
| Q1 25 | 2.8% | 9.5% | ||
| Q4 24 | — | 11.0% | ||
| Q3 24 | -85.1% | 12.0% | ||
| Q2 24 | 10.6% | 13.8% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.33 | ||
| Q3 25 | $0.12 | $0.49 | ||
| Q2 25 | $-0.11 | $0.45 | ||
| Q1 25 | $0.10 | $0.33 | ||
| Q4 24 | $0.38 | $0.40 | ||
| Q3 24 | $-3.11 | $0.44 | ||
| Q2 24 | $0.39 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | — |
| Total Assets | $1.2B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $295.0M | ||
| Q3 25 | $246.3M | $255.0M | ||
| Q2 25 | $445.9M | $272.0M | ||
| Q1 25 | $493.6M | $267.0M | ||
| Q4 24 | $484.6M | $298.0M | ||
| Q3 24 | $453.8M | $327.0M | ||
| Q2 24 | $404.2M | $295.0M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $491.0M | ||
| Q3 25 | $376.7M | $544.0M | ||
| Q2 25 | $580.5M | $608.0M | ||
| Q1 25 | $583.4M | $653.0M | ||
| Q4 24 | $585.3M | $742.0M | ||
| Q3 24 | — | $797.0M | ||
| Q2 24 | — | $810.0M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $1.3B | ||
| Q3 25 | $727.2M | $1.2B | ||
| Q2 25 | $757.8M | $1.1B | ||
| Q1 25 | $798.5M | $970.0M | ||
| Q4 24 | $778.3M | $904.0M | ||
| Q3 24 | $749.6M | $872.0M | ||
| Q2 24 | $879.3M | $769.0M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.5B | $2.9B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.5B | $2.9B | ||
| Q2 24 | $1.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.39× | ||
| Q3 25 | 0.52× | 0.46× | ||
| Q2 25 | 0.77× | 0.56× | ||
| Q1 25 | 0.73× | 0.67× | ||
| Q4 24 | 0.75× | 0.82× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
ULS
Segment breakdown not available.
